PHG PHG
Company Profile ↓Company Overview
PHG (PHG) is a publicly traded company listed on with a market capitalization of $25.60B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Net profit has compounded at 51.9% per year over the last five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $17.83B (-1.0% YoY); net profit $895.00M.
- Trailing 12 Months Year-on-year growth — revenue -1.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.0%, profit CAGR 51.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.01% |
| 1 Year: | -1.04% |
Compounded Profit Growth
| 5 Years: | 51.89% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +3.39% |
| 6 Months: | -4.80% |
| 3 Months: | +4.45% |
| 1 Month: | -5.81% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)50.93 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 51.9% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 4.34B | 4.30B | 5.10B | 3.90B | 4.36B |
| Cost of Revenue | 2.33B | 2.39B | 2.81B | 2.14B | 2.21B |
| Gross Profit | 2.01B | 1.91B | 2.29B | 1.77B | 2.15B |
| Operating Expenses | 1.61B | 1.58B | 1.72B | 1.52B | 1.54B |
| Operating Income | 401.00M | 330.00M | 565.00M | 242.00M | 610.00M |
| EBITDA | 683.00M | 656.00M | 800.00M | 538.00M | 1.02B |
| Interest Expense | 80.00M | 78.00M | 56.00M | 83.00M | 95.00M |
| Pretax Income | 337.00M | 275.00M | 466.00M | 190.00M | 546.00M |
| Tax Provision | 95.00M | 87.00M | 74.00M | 44.00M | 160.00M |
| Net Income | 240.00M | 184.00M | 395.00M | 151.00M | 384.00M |
| Diluted EPS | 0.25 | 0.19 | 0.42 | 0.16 | 0.40 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 17.83B | 18.17B | 18.02B | 17.83B |
| Cost of Revenue | 10.63B | 10.72B | 10.25B | 9.78B |
| Gross Profit | 7.19B | 7.45B | 7.77B | 8.06B |
| Operating Expenses | 7.37B | 7.62B | 7.26B | 6.61B |
| Operating Income | -177.00M | -168.00M | 513.00M | 1.45B |
| EBITDA | 115.00M | 1.04B | 1.85B | 2.60B |
| Interest Expense | 244.00M | 306.00M | 337.00M | 294.00M |
| Pretax Income | -1.73B | -526.00M | 123.00M | 1.18B |
| Tax Provision | -113.00M | -73.00M | 963.00M | 282.00M |
| Net Income | -1.61B | -466.00M | -702.00M | 895.00M |
| Diluted EPS | -1.68 | -0.49 | -0.75 | 0.94 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 30.69B | 29.41B | 28.98B | 26.94B |
| Current Assets | - | 10.26B | 9.94B | 10.02B | 9.93B |
| Cash & Equivalents | - | 1.17B | 1.87B | 2.40B | 2.79B |
| Inventory | - | 4.05B | 3.49B | 3.20B | 2.87B |
| Receivables | - | 3.83B | 3.73B | 3.51B | 3.34B |
| Total Liabilities | - | 17.41B | 17.34B | 16.93B | 15.96B |
| Current Liabilities | - | 7.93B | 8.29B | 8.14B | 7.51B |
| Long Term Debt | - | 6.17B | 6.09B | 6.19B | 6.05B |
| Total Debt | - | 7.34B | 7.61B | 7.49B | 7.81B |
| Total Equity | - | 13.25B | 12.03B | 12.01B | 10.96B |
| Shares Outstanding | - | 952.31M | 944.73M | 939.94M | 962.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -173.00M | 2.14B | 1.57B | 1.17B |
| Investing Cash Flow | - | -1.49B | -636.00M | -573.00M | -737.00M |
| Financing Cash Flow | - | 500.00M | -848.00M | -496.00M | 107.00M |
| Capital Expenditure | - | -806.00M | -644.00M | -676.00M | -668.00M |
| Free Cash Flow | - | -979.00M | 1.49B | 893.00M | 504.00M |
| Net Change in Cash | - | -1.17B | 776.00M | 487.00M | 532.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 40.4% | 41.0% | 43.1% | 45.2% |
| Operating Margin % | -1.0% | -0.9% | 2.8% | 8.1% |
| Net Margin % | -9.0% | -2.6% | -3.9% | 5.0% |
| ROE % | -12.1% | -3.9% | -5.8% | 8.2% |
| ROCE % | -0.8% | -0.8% | 2.5% | 7.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PHG
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation
VIENNA, August 05, 2026--Philips SpeechLive Legal AI Assistant turns voice and uploaded sources into structured legal documents using legal speech recognition and AI drafting.
Philips Avent introduces new automated SMS-based tool to help moms activate their village during postpartum
Philips (NYSE: PHG, AEX: PHIA), a global leader in mother and child care and women's health, announced today the launch of the Philips Avent Share the Care Connector, a new SMS-based support tool designed to help moms seamlessly organize an…
[Latest] Global AI in Medical Imaging Market Size/Share Worth USD 19.4 Billion by 2035 at a 20.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global AI in Medical Imaging Market size & share revenue was valued at approximately USD 2.9 Billion in 2025 and is e…
Philips (ENXTAM:PHIA) Reports Strong Q2 Growth And Raises Full Year Outlook
Koninklijke Philips (ENXTAM:PHIA) reported strong Q2 2026 growth across its main business segments. The company completed a significant US tariff refund that had previously affected its earnings profile. Philips raised its full year outlook…
Philips Q2 Earnings and Revenues Increase Year over Year, Shares Down
PHG lifts its 2026 profit and free cash flow outlook after Q2 earnings increase on higher sales, productivity gains and a U.S. tariff refund benefit.
Philips Gets a Tariff Refund, Not a Clean Bill of Health
The Dutch medtech group beat expectations and lifted margin guidance, but weaker orders left investors worrying about the second-half scan.
PHG — Frequently Asked Questions
What is the current share price of PHG?
As of 2026-08-05 17:25 PDT, PHG trades at $26.59 on NASDAQ/NYSE. Its 52-week range is $24.62 to $31.68.
What is the market capitalisation of PHG?
PHG has a market capitalisation of $25.60B on NASDAQ/NYSE.
What is the P/E ratio of PHG?
PHG trades at a trailing price-to-earnings (P/E) ratio of 28.29. Its price-to-book (P/B) ratio is 2.34.
What is the return on equity (ROE) of PHG?
PHG has a return on equity (ROE) of 8.17%. Its return on capital employed (ROCE) is 7.46%.
Is PHG a good stock to buy?
This page provides a data-driven analysis of PHG, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.